Current oncology最新文献

{"title":"Correlation of <i>TP53</i> Genetic Alterations with p53 Immunohistochemical Expression and Their Prognostic Significance in DLBCL.","authors":"Chen Chen, Zijuan Hu, Min Ren, Longlong Bao, Ran Wei, Tian Tian, Xiaoli Zhu, Qianming Bai, Baohua Yu, Xiaoqiu Li, Xiaoyan Zhou","doi":"10.3390/curroncol32090488","DOIUrl":"10.3390/curroncol32090488","url":null,"abstract":"<p><p><i>TP53</i> genetic alterations represent a critical molecular feature in diffuse large B-cell lymphoma (DLBCL), with well-established associations with aggressive disease behavior and therapeutic resistance. However, significant controversy persists regarding the clinical utility of p53 immunohistochemical (IHC) expression as a surrogate marker. This study presents a thorough investigation of <i>TP53</i> genetic alterations and their correlation with p53 protein expression in 664 cases of DLBCL. Using targeted next-generation sequencing (tNGS), we identified <i>TP53</i> alterations (mutations and/or copy number losses (CNLs)) in 170 cases (25.6%). Among them, 161 cases had mutations. Concurrent analysis of copy number variations (CNVs) in 109 cases revealed <i>TP53</i> CNLs in 17.4% (19/109), with 68.4% (13/19) of these showing coexisting mutations. Immunohistochemical evaluation of p53 expression in 371 cases demonstrated strong positivity (≥65% cells) in 21% (78/371), complete negativity (<1%) in 5.7% (21/371), and wild-type pattern (1-65%) in 73.3% (272/371) of cases. The p53 IHC laboratory-developed test (LDT) showed 79.2% sensitivity and 91.6% specificity for detecting <i>TP53</i> alterations overall, though sensitivity varied significantly by mutation type: 86.2% for missense mutations but only 14.3% for nonsense mutations. Clinically, cases with <i>TP53</i> alterations exhibited more aggressive disease characteristics, including higher ECOG performance scores, increased frequency of B symptoms, and poorer initial treatment responses (complete response rate 68.3% vs. 82.5% in wild-type cases). Most importantly, <i>TP53</i> genetic alterations, but not p53 protein expression patterns, emerged as an independent prognostic factor for progression-free survival. Our findings demonstrate that tNGS effectively identifies most <i>TP53</i> alterations and complementary CNV analysis enhances detection of copy number losses. The p53 IHC LDT serves as a useful but imperfect screening tool, with high specificity but variable sensitivity depending on mutation types. These results have important implications for molecular diagnostics in DLBCL, supporting the necessity for comprehensive genetic testing rather than reliance on protein expression analysis alone for accurate risk stratification and treatment planning.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Disparities in Who Accepts an Early Palliative Care Consultation.","authors":"Heather Halperin, Philip Akude, Seema King, Patricia Biondo, Aynharan Sinnarajah, Desiree Hao, Jessica Simon","doi":"10.3390/curroncol32090485","DOIUrl":"10.3390/curroncol32090485","url":null,"abstract":"<p><p>Early palliative care improves quality of life for patients with life-limiting illnesses, but access is often inequitable. The goal of this study was to assess disparities in early specialist palliative care (SPC) consultation among newly diagnosed stage IV lung cancer patients. All newly diagnosed stage IV lung cancer patients in southern Alberta, Canada (June 2021-March 2022) were offered SPC consultations from a multidisciplinary team, post-oncology visit. A retrospective chart review analyzed demographic factors and consultation outcomes (accepted, ineligible, declined/unreachable), using the Pampalon Deprivation Index and NamSor surname analysis as proxies for equity-related variables. Of 113 patients, 76.2% were eligible for consultation, and 67.4% of those accepted consultation. Older age (>65 years), male sex, and high deprivation were linked to declining SPC (<i>p</i> < 0.05-0.01). Conversely, living alone or with a non-partner increased acceptance (<i>p</i> < 0.05). Age, sex, deprivation, and living situation influenced SPC acceptance. Identifying disparities can guide interventions to improve equitable access.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of Posttraumatic Growth Among Latvian Parents of Children with Cancer: A Mixed Methods Approach.","authors":"Inese Lietaviete, Reinis Alksnis, Baiba Martinsone","doi":"10.3390/curroncol32090486","DOIUrl":"10.3390/curroncol32090486","url":null,"abstract":"<p><strong>Background: </strong>This study explores post-traumatic growth (PTG) among parents of childhood cancer survivors (CCSs), a group often underrepresented in research.</p><p><strong>Method: </strong>A convergent parallel mixed-methods design integrating Bayesian Multilevel Latent Class Analysis and Thematic Analysis was utilized in a longitudinal study involving 58 caregivers (50 mothers, 8 fathers) from the Children's Clinical University Hospital in Riga. Quantitative data were collected at diagnosis using the Psychosocial Assessment Tool (PAT) and Big Five Inventory-10 (BFI-10). Follow-up assessments post-treatment included the Responses to Stress Questionnaire (RSQ), Impact of Event Scale-Revised (IES-R), and the Post-traumatic Growth Inventory (PTGI). Qualitative data were collected through structured interviews.</p><p><strong>Results: </strong>A 2-class model distinguished parents with low PTG from those with moderate to high PTG. Change in values, detachment from trivial stressors, and acceptance of life emerged as key indicators of growth. PTG was not significantly correlated with overall post-traumatic stress symptoms, but engagement coping strategies showed a positive association with PTG and personality traits like extraversion and openness.</p><p><strong>Conclusions: </strong>The mixed methods approach revealed sample-specific PTG elements not reflected in standardized tools. Initial perceptions of the cancer diagnosis shaped psychological outcomes, with PTG facilitated by adaptive coping, self-reflection, support, emotional disclosure, and psychological struggle. This study offers the first insights into PTG among Latvian parents of CCSs, a previously unexplored area.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding.","authors":"Madeline Monaghan, An Duong, Kalina Abrol, Trang Doan, Carolina Cieniak, Harold Atkins, Natasha Kekre, Ashish Masurekar, Ram Vasudevan Nampoothiri, Santhosh Thyagu, Christopher N Bredeson, Michael Kennah, David S Allan","doi":"10.3390/curroncol32090483","DOIUrl":"10.3390/curroncol32090483","url":null,"abstract":"<p><p>The reasons why patients cannot proceed with HCT, including cases where no suitable donor is identified, remain poorly described. We reviewed all referrals for allogeneic HCT to our programme between 1 January 2019 and 31 December 2023. Of 880 patients referred for allogeneic HCT, 494 (61.8%) proceeded to transplant (mean 52 ± 14.8 years, 61.5% male) using HLA-matched unrelated (64.2%) or related (19.4%) donors and HLA-mismatched (13%) or haploidentical (3%) donors. Of patients that did not proceed with HCT (386, 38.2%), disease-related causes (54.2%), patient preference (15.8%), and significant patient comorbidity (11.4%) were the most common reasons. Eleven patients (2.9% of transplants that did not proceed; 1.3% of all referrals) lacked a suitable donor and had HLA phenotypes most associated with Caucasian (six patients, 55%), First Nations, Inuit or Metis (two patients, 18%), Black African, Caribbean or African American (one patient, 9%), Asian or Pacific Islander (9%), or unknown ethnicity (one patient, 9%). Very few patients were unable to proceed with transplant due to lack of a suitable donor; however, those cases are overrepresented by non-Caucasian ethnicity relative to the population.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rethinking Clinical Trials (REaCT) Program: A Pragmatic Research Strategy to Improve Cancer Care for Patients, Caregivers, and Healthcare Systems.","authors":"Marie-France Savard, Mark Clemons, Sharon F McGee","doi":"10.3390/curroncol32090484","DOIUrl":"10.3390/curroncol32090484","url":null,"abstract":"<p><p>Cancer care has become increasingly complex, expensive, and inaccessible, with patients often exposed to increased treatment-related harms for marginal benefits. Pragmatic clinical trials offer a solution by conducting real-world studies that evaluate dose optimization, toxicity, quality of life, and resource utilization. Pragmatic trials can also address the efficacy-effectiveness gap: the poorer outcomes and greater toxicity observed in everyday practice compared to those reported in many clinical trials. The Rethinking Clinical Trials (REaCT) program was designed to conduct patient-centered practice-changing research by involving patients, their families, and healthcare providers in the design of inclusive, real-world clinical trials. The REaCT process starts with surveys and systematic reviews to identify knowledge gaps and uses this information to design pragmatic clinical trials that address these deficits. Since 2014, the program has conducted 17 patient and 17 healthcare provider surveys with 2298 and 1033 responses, respectively. With these results, the program has performed 22 systematic reviews. These surveys and systematic reviews have resulted in 19 completed and 8 ongoing REaCT clinical trials that have recruited over 5000 patients from across Canada. Here, we present some of the practice-changing research conducted by the REaCT program and address challenges facing the growth of pragmatic research.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Transplantation for Unresectable Colorectal Liver Metastases: A Scoping Review on Redefining Boundaries in Transplant Oncology.","authors":"Berkay Demirors, Vrishketan Sethi, Abiha Abdullah, Charbel Elias, Francis Spitz, Jason Mial-Anthony, Godwin Packiaraj, Sabin Subedi, Shwe Han, Timothy Fokken, Michele Molinari","doi":"10.3390/curroncol32090481","DOIUrl":"10.3390/curroncol32090481","url":null,"abstract":"<p><p>Historically, colorectal liver metastases (CRLMs) have been considered a contraindication for liver transplantation (LT), primarily due to limited organ availability and concerns about oncologic efficacy. However, emerging evidence indicates that highly selected patients with unresectable CRLM can achieve long-term survival following LT-often with outcomes superior to those obtained through conventional systemic therapies. To evaluate the evolving role of LT in this setting, we conducted a scoping review of the literature. A comprehensive search was performed across PubMed, Embase, Web of Science, Scopus, and ClinicalTrials.gov, as well as ProQuest Dissertations & Theses and Google Scholar to capture gray literature. The search included English-language articles published between January 2015 and April 2025. Eligible studies included those reporting on the application of LT for patients with unresectable CRLM. This scoping review synthesizes current evidence on patient selection criteria, overall and disease-free survival, recurrence patterns, and emerging biomarkers that may guide transplant eligibility. In addition, we explore innovations in organ utilization-including living donor LT and machine perfusion technologies-that aim to expand access while addressing ethical concerns related to organ allocation. As LT for CRLM transitions from investigational use to clinical implementation, this review outlines the key challenges and future opportunities that will shape its role in the landscape of transplant oncology.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-Escalation of Treatment in Women Aged ≥80 Years with Breast Cancer: A Retrospective Analysis from Two Breast Centers.","authors":"Gianmarco Piccolino, Giulia Cardelli, Francesca Arienzo, Emanuele Zarba Meli, Elena Del Giudice, Leopoldo Costarelli, Rosalinda Rossi, Claudia Scaringi, Tiziana Mastropietro, Laura Broglia, Valeria Vitale, Federica Bergamo, Elena Manna, Massimo La Pinta, Lorenzo Palleschi, Andrea Loreti, Augusto Lombardi, Lucio Fortunato","doi":"10.3390/curroncol32090482","DOIUrl":"10.3390/curroncol32090482","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is frequently diagnosed in older women. However, the impact of surgery on survival is not well studied and prognosis for women ≥ 80 years of age is progressively depending on comorbidities.</p><p><strong>Methods: </strong>Medical records of consecutive women aged ≥ 80 years diagnosed with primary breast cancer treated with upfront surgery at two Breast Centers from 2011 to 2021 were retrospectively analyzed.</p><p><strong>Results: </strong>A total of 553 consecutive women with a median age of 83 years and a median tumor diameter of 21 mm were analyzed (574 lesions). Clinical Stages II or III were found in 263/574 (46%) and 101/574 cases (18%), respectively. Axillary staging was completely omitted for 94/542 invasive lesions (17%), and this increased over time from 2% to 33% (<i>p</i> < 0.001). Adjuvant hormone therapy and radiotherapy were omitted in 134/490 (27%) and in 122/420 patients (29%), respectively, while only 26/195 (13%) of patients with a clear clinical indication received adjuvant chemotherapy. At a median follow-up of 61 months (6-147) the 5- and 10-years overall survival (OS) were 64% and 21%, while breast cancer-specific survival (BCSS) at 5 and 10 years were 94% and 78%, respectively. Adjuvant therapies were not associated with a significant improvement in BCSS, while worse OS was associated with older age or more comorbidities as measured by the Charlson Comorbidity Index (CCI) (<i>p</i> < 0.001 and <i>p</i> = 0.012, respectively).</p><p><strong>Conclusions: </strong>Breast surgery, when possible, has a primary role even for women > 80 years of age, and it is associated with a reasonable BCSS. De-escalation of adjuvant therapies should be considered in this setting because survival is largely determined by age and co-morbidities.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Stratified Clinicopathological Features and Efficacy of Adjuvant Chemotherapy in Resectable Gastric Cancer: An East-West Population-Based Study.","authors":"Zijian Deng, Jianping Guo, Zhizhong Xiong, Bin Zhong, Dayin Huang, Haoyang Xu, Shi Chen, Lei Lian","doi":"10.3390/curroncol32090480","DOIUrl":"10.3390/curroncol32090480","url":null,"abstract":"<p><p><b>Background:</b> The incidence of early-onset gastric cancer (EOGC) has been steadily increasing in recent years. However, the efficacy of adjuvant chemotherapy (AC) in this population remains unclear. This study aimed to investigate the clinicopathological characteristics, survival outcomes, and efficacy of AC between EOGC and average-onset gastric cancer (AOGC) patients. <b>Methods:</b> Patients with stage II-III gastric adenocarcinomas who underwent curative D2 gastrectomy at the Sixth Affiliated Hospital of Sun Yat-sen University from January 2014 to December 2021 were enrolled and classified into two groups: EOGC (≤45 years) and AOGC (>45 years) groups. Clinicopathological characteristics, overall survival (OS), and efficacy of AC were compared between the two groups. Western and East Asian cohorts were included as external validation sets to compare the efficacy of AC between different age groups. <b>Results:</b> Compared to AOGC, EOGC patients exhibited a higher proportion of females, poor differentiation, diffuse Lauren type, middle-third GC, perineural invasion (PNI), and receipt of AC. Univariate and multivariate analyses identified that T stage, N stage, PNI, and AC were independent prognostic factors for OS. After balancing the baseline characteristics between patients who received AC and those who did not, the Kaplan-Meier survival curves indicated that AC significantly improved OS across all patients. Further subgroup analysis revealed a survival benefit of AC in AOGC patients, whereas no significant survival difference was observed in the EOGC subgroup. Consistently, external validation in both Western and East Asian cohorts confirmed that AC did not confer a survival advantage in EOGC patients. <b>Conclusions:</b> EOGC exhibits aggressive pathological characteristics, and chemotherapy does not consistently improve survival in EOGC patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Therapeutic Development for Nasopharyngeal Carcinoma.","authors":"Jongwoo Kim, Yunjoo Lee, Seoin Kim, Jong Chul Park","doi":"10.3390/curroncol32090479","DOIUrl":"10.3390/curroncol32090479","url":null,"abstract":"<p><p>Nasopharyngeal carcinoma (NPC) is a rare malignancy with a distinct epidemiological pattern and is most often associated with Epstein-Barr virus (EBV). EBV plays a critical role in NPC pathogenesis, with viral proteins driving oncogenesis by altering immune regulation, apoptosis, and tumor progression. The unique molecular landscape of NPC presents both challenges and opportunities for therapeutic development, particularly in the recurrent and metastatic (R/M) setting, where treatment resistance remains a major hurdle. While platinum-based chemotherapy has traditionally been the standard of care for R/M NPC, immune checkpoint inhibitors (ICIs) have emerged as a key component of treatment. However, both intrinsic and acquired resistance to PD-1/PD-L1 blockade underscore the need for alternative strategies, including modulation of alternative immune checkpoints and simultaneous engagement of non-redundant pathways to enhance responses and durability. Leveraging EBV-driven biology, emerging immunotherapeutic approaches, such as EBV-specific adoptive cellular therapies and therapeutic vaccines, aim to induce durable immunity to viral proteins. Additionally, targeted therapies including receptor tyrosine kinase inhibitors, epigenetic modulators, and antibody-drug conjugates are redefining precision medicine by selectively delivering cytotoxic agents to tumors. With growing insights into the biology of NPC and evolving therapeutics, the integration of immunotherapy, targeted agents, and biomarker-driven strategies is poised to transform NPC treatment, emphasizing biology-driven, multimodal approaches to optimize patient outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Oncology in 2025: Challenges, Innovations, and the Road Ahead for Young Surgical Oncologists.","authors":"Jörg Kleeff, Artur Rebelo","doi":"10.3390/curroncol32090478","DOIUrl":"10.3390/curroncol32090478","url":null,"abstract":"<p><p>As cancer care becomes increasingly complex and multidisciplinary, the role of surgical oncology continues to evolve at the forefront of innovation [...].</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}